There is evidence that sulphasalazine is an effective second line agent in the treatment of rheumatoid arthritis. 1-6 Most of the data in these reports relate to the ability of the drug to suppress both the clinical and laboratory features of disease activity and there is no information about outcome measures such as radiological evidence of erosive disease. One of the major practical problems encountered in generating such data is our inability to maintain a truly representative placebo control group over an adequate period7 because lack of symptomatic benefit causes patients to withdraw from a placebo group in the first year of study. A number of methods of radiological assessment have been attempted in order to overcome this problem, but none has proved satisfactory. The A six month follow up of these patients has previously been described. 15 Radiographs of hands, hip, and knees were taken at 0, 1, and 2 years. Hand radiographs were assessed using a previously described and validated'3 modification of Sharp's method'6; hip and knee radiographs were scored using Larsen's standard films'7 and the four scores for large joints totalled. All films were read blind: hands by TP and large joints by HAC. 'Control' hand radiographs from 0 and 2 year assessments of 10 patients with active disease who repeatedly declined our offers of second line therapy were read blind by TP. The 'control' score on this occasion showed good correlation with the previous reading of these same films four years previously (rs=0*9625). At the start of the study hand radiograph scores did not differ significantly between the 'control' (median 62) and sulphasalazine (median 57) patients (p=0853; Mann-Whitney).
Results
Sixty three (42%) patients continued to receive sulphasalazine for two years. Forty four discontinued therapy because of adverse effects, 26 stopped because of lack or loss of efficacy, and 17 for miscellaneous other reasons. Hand radiographs at 0 and 2 years were available for 41 patients, 31 of these had hand x rays available for 0, 1, and 2 years. Twenty one patients also had hip and knee radiographs available at 0, 1, and 2 years. No statistical differences in the starting values for any demographic or inflammatory indices could be shown between those who continued therapy and those who stopped, or between any of the subgroups defined by the availability of radiographs (MannWhitney; p>0-05 in all cases) ( Table 1 ).
Significant improvement in inflammatory parameters between 0 and 2 years was seen in all subgroups. This improvement had occurred by three months and showed no significant change over the subsequent 21 months. Table 1 shows medians, confidence intervals, and p values for the group of 41 patients whose 0 and 2 year films were available and for the 63 patients who completed two years' therapy; a similar pattern was seen in the subgroups of 31 patients who also had one year films and of 21 patients for whom large joint radiographs were available.
Significant deterioration was seen in hand radiograph scores between 0 and 2 years in the 41 patients and in the subgroup of 31 who also had week 48 films. The median changes (95% confidence intervals) were +4 (+1 -+9) and +5 (+1 -+9) respectively (p=0.0004 and 0-0007 respectively; Wilcoxon 0 v 2 years). The median change in the ,control' group was +11 (+7 -+19) (p=0.0367; Wilcoxon year 0 v 2) (Figs 1 and 2) . The change in 'control' values was significantly greater than that in the group of 31 (p=00448; Mann-Whitney), but the Wilcoxon: week () v wcck 96 *=p<()0-5; **=p<0-01; ***=p<0-005; ****=p<(-().
second years failed to reach significance (p=0-156; Mann-Whitney). Large joint radiographs showed a median score of 6 (95% confidence limits 2-9) at time 0 and of 7 (95% confidence limits 2-10) at two difference did not reach statistical significance when compared with the change in the group of 41 patients (p=00747; Mann-Whitney).
In the group of 31 patients in whom 0, 1, and 2 year hand films were available a significant deterioration was seen during the first year but no significant change was seen during the second year ( Table 2 ). The degree of change over the first and second 48 week periods also differed significantly (p=0-0182; Mann-Whitney). This pattern was maintained even in those 21 patients whose ESR failed to remain below 30 mm/h at one and two years, although in this case comparison of the change in the radiograph score over the first and second years failed to reach statistical significance (p=0 106; Mann-Whitney). In the 10 patients who maintained their ESR at <30 mm/h at one and two years a significant deterioration was seen during the first but not the second year, but again comparison of the change in the radiograph score over the first and 
Discussion
Unfortunately radiographs were not available in all patients who completed two years of therapy. Disease activity at the outset of treatment and changes during treatment, however, were no different in the patients who films were available than in the whole group who achieved two years of therapy.
The most important finding in this study is the slowing of radiological progression during the second year of sulphasalazine therapy. Previously such a slowing with second line drugs has been shown convincingly only in a subgroup of patients whose ESR or C reactive protein returned to normal,"1 although in that study change in the second six month period was compared with that in the first. In our study the lack of significant deterioration during the second year was seen even in patients whose ESR failed to remain below 30 mm/h, though it can be assumed that all patients who remained on therapy did show a clinically significant symptomatic improvement compared with week 0. As in previous studies, change in hand radiograph score did not correlate significantly with change in inflammatory indices,'2 and this suggests that the criteria which we use to identify a second line drug (improvement in clinical and laboratory parameters of inflammation) are not necessarily important in determining the longer term outcome as measured by radiological changes. Rheumatoid arthritis, however, is a chronic disease and the inflammatory phase can last over 20 years. Thus, although the results described here are promising, it will be necessary to investigate whether this slowing of deterioration continues over subsequent years.
It is also noteworthyxthat in view of our previous calculation predicting the number of patients who would have to continue to receive gold or penicillamine (120 and 161 respectively) over a two year period (with a similar sized control group) to show a significant difference in the slowing of erosive disease'3 that we attained p values around the 5% level with groups of 31 and 41 patients treated with sulphasalazine. Interpretation of this information is difficult. It is possible that sulphasalazine has a more marked effect on radiological progression than does gold or penicillamine, but we have no firm evidence of this, and a formal trial to investigate this point further would require large numbers of patients treated concurrently. An alternative explanation is that the increase in the number of second line drugs had made us less tolerant of partial response to 'second line' therapy-the large numbers of patients discontinuing therapy because of lack/loss of effect would tend to support this possibility. In an ideal world an intention to treat analysis would be an important method of resolving this question. In the real world, however, most patients who discontinue one second line drug proceed to another such agent (over 80% of patients in our study), and such an analysis would therefore only cloud the issue further.
It is of interest that there was no significant change in large joint radiographs over two years despite a weak correlation between the changes in large joint scores and hand scores. This may reflect a true lack of progression (perhaps related to therapy) but is more likely merely to represent the lack of sensitivity of the semi-objective Larsen method for assessing deterioration in large joints.
No attempt has been made to investigate the relationship of dose of sulphasalazine to radiological progression as at the end of the two year period patients had achieved a wide range of doses which suited them in terms of side effects and symptomatic relief and the numbers on any one dose would have been insufficient for a meaningful comparison to take place.
We conclude that sulphasalazine produced a slowing of radiological deterioration in the small joints of the hands during the second year of therapy in the minority of patients who continue therapy for two years. This effect is independent of improvement in inflammatory parameters. In addition, when compared with a self selected 'control' group there is a tendency, with equivocal statistical significance, for radiological progression to be retarded over the first two years of therapy. Such results are at least promising when compared with our previous assessment of gold and penicillamine.13 
